Indoco Remedies Q1FY27: Profit up on ₹97cr sale gain

Key takeaway from the quarter

Indoco Remedies Ltd reported a sharp turnaround in Q1FY27, but the improvement was driven mainly by a one-time gain rather than stronger operations. The company posted standalone net profit of ₹8.23 crore for the quarter ended June 30, 2026, compared with a loss of ₹2.81 crore in Q1FY26. Management-approved results were taken on record at the Board meeting held on July 28, 2026. The results were reviewed by the Audit Committee and underwent a limited review by statutory auditors. Auditors M/s Gokhale & Sathe, Chartered Accountants, issued an unmodified opinion on the quarterly financials.

Board approval and regulatory disclosure

Indoco said the Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The approval was stated as being under Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Separately, the company had also communicated a trading window closure for designated persons and their immediate relatives. The window was stated to remain closed until July 30, 2026, which is 48 hours after the declaration of results.

Standalone results: revenue up, margin improves

Standalone revenue from operations rose 5.8% year-on-year to ₹40.81 crore in Q1FY27 from ₹38.56 crore in Q1FY26. The revenue mix showed domestic sales of ₹22.78 crore and exports of ₹18.04 crore for the quarter. EBITDA margins improved to 10.3% in Q1FY27, up from 3.8% in the corresponding quarter last year. In value terms, EBITDA was reported at ₹42.2 crore, compared with ₹14.8 crore in Q1FY26, as cited in the results note. The company attributed the margin improvement to better cost management and mix shifts.

Profit turnaround driven by ophthalmic division sale

The standout item in the quarter was an exceptional gain from the sale of the Ophthalmic Business Division. Indoco recognised an exceptional gain of ₹97.34 crore from the slump sale of the division to Sunways (India) Private Limited. This non-operating gain was the primary reason for the reported profit turnaround. The quarter’s reported standalone net profit of ₹8.23 crore therefore reflected a significant boost from the asset sale.

Underlying operations still loss-making

The reported profit figure masked the weakness in the underlying business, as indicated by the company’s disclosure on profit before tax excluding the exceptional item. Without the one-time gain, Indoco recorded a standalone pre-tax loss of ₹4.12 crore before exceptional items and tax. This divergence between reported profitability and operating performance was a key feature of the quarter. The results note indicated that core operational challenges remain, despite the improvement in EBITDA margin and modest revenue growth.

Consolidated performance: profit returns, sales rise 8.2%

On a consolidated basis, revenue from operations increased 8.2% year-on-year to ₹46.62 crore in Q1FY27 from ₹43.09 crore in Q1FY26. Domestic sales were reported at ₹31.18 crore, while international sales were ₹15.45 crore for the quarter. Consolidated net profit attributable to equity shareholders came in at ₹6.50 crore, compared with a loss of ₹3.58 crore in Q1FY26. The consolidated numbers also included the same exceptional gain of ₹97.34 crore from the ophthalmic business sale.

Auditor note: going concern risk flagged at subsidiary

Alongside the unmodified opinion on the quarterly results, auditors highlighted a material uncertainty on the going concern status of subsidiary FPP Holding LLC. The disclosure stated that FPP Holding LLC continued to have a negative net worth of ₹38.23 crore. At the same time, it earned a net profit of ₹3.01 crore during the quarter. The auditor flag indicates that despite quarterly profitability at the subsidiary level, the balance sheet position remained stressed, based on the negative net worth figure cited.

Stock price snapshot from the disclosures

Market data included alongside the results showed Indoco Remedies shares at ₹246.25 on BSE, down 2.38%, and ₹246.23 on NSE, down 2.25%, as per the cited update. The same data block also carried a 52-week range of ₹163.70 to ₹348.10. In another market update included in the material, the stock was stated to be trading at ₹251, up 0.99% at 1:22 PM, with 71,415 shares traded during the session. These quotes were presented as snapshots in the provided market feed.

Key reported numbers (all amounts in ₹ crore)

*Consolidated figures represent profit attributable to equity shareholders.

What investors will track after Q1FY27

The quarter’s disclosures leave investors with two parallel threads to monitor. One is the impact of the ophthalmic division sale on reported earnings and financial position, given the magnitude of the exceptional gain. The second is whether the operating business can move toward sustainable profitability, since the company disclosed a pre-tax loss of ₹4.12 crore excluding exceptional items. The auditor’s going concern emphasis for FPP Holding LLC also remains a key risk marker, especially with the subsidiary’s negative net worth of ₹38.23 crore. Any subsequent updates on the subsidiary’s capital structure and operations will be closely watched.

Conclusion

Indoco Remedies’ Q1FY27 results show a headline profit turnaround supported largely by a ₹97.34 crore exceptional gain from an asset sale, while core operations remained under pressure. The next set of updates is likely to be driven by follow-through on operational performance and any further disclosures around the subsidiary flagged by auditors.